Generalizability of Glucagon‐Like Peptide‐1 Receptor Agonist Cardiovascular Outcome Trials to the Overall Type 2 Diabetes Population in the United States
2019
Aim To examine the generalizability of results from glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) cardiovascular outcome trials (CVOTs) in the US type 2 diabetes (T2D) population.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
16
References
23
Citations
NaN
KQI